Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial (Q73026352)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

primary biliary cholangitis

31 October 2019

main subject

0 references

author name string

M Leuschner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

K P Maier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Schlichting

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S Strahl

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

G Herrmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H H Dahm

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

H Ackermann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J Happ

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

U Leuschner

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

language of work or name

English

0 references

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

918-925

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Oral budesonide in active Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

High performance liquid chromatographic determination of free and conjugated bile acids in serum, liver biopsies, bile, gastric juice and feces by fluorescence labeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Inhibitory effect of glucocorticosteroids on anti-IgE-induced histamine release from human basophilic leukocytes: evidence for a dual mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

The glucocorticosteroid, budesonide, partially blocks histamine release from human lung tissue in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Systemic side-effects of three topical steroids in diseased skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

Oral budesonide for treatment of autoimmune chronic active hepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970351-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(99)70351-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500075%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference